TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with documented HIV-1 infection~* Patient has never been treated with a therapeutic HIV vaccine or an ARV drug prior to screening~* Patient's HIV-1 plasma viral load at screening is \> 5,000 HIV-1 RNA copies/mL (assayed by RNA PCR standard specimen procedure)~* Patient's virus is sensitive to the 2 nucleoside/nucleotide reverse transcriptase inhibitors chosen for treatment~* Patient agrees not to start ART before the baseline visit~* Patient is HLA-B\*5701 negative in case abacavir is included in the patient's treatment regimen.~Exclusion Criteria:~* Previous use of ANY ARV drug for ANY length of time~* Any documented evidence of NNRTI resistance associated mutations in patient's HIV~* Category C AIDS defining illness, except, Stable Kaposi Sarcoma Wasting syndrome if not progressive~* Pneumocystis carinii pneumonia (PCP) that is considered not cured~* Active TB~* Allergy or hypersensitivity to study or background ARTs~* Specific grade 3 or 4 toxicity~* Kidney impairment: calculated creatinine clearance \<50 ml/min

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- 002 (Type: ACTIVE_COMPARATOR): efavirenz 600 mg tablet once daily for 96 weeks
- 001 (Type: EXPERIMENTAL): TMC278 25 mg tablet once daily for 96 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Hyporesponse in Healthy Elderly Participants (MK-0000-131 AM2)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 25 to 40 years old or 65 years of age or older at the prestudy (screening) visit~* Has no fever on day of screening~* Lacks Hepatitis B surface antigen seroreactivity~* If female 25 to 40 years of age, is not pregnant nor breastfeeding, and agrees to use effective contraception~Exclusion Criteria:~* Has a prior history of Hepatitis B Virus infection~* Has BMI (Body Mass Index) \>35~* If female 25 to 40 years of age, is pregnant, or expecting to conceive, donate eggs or breastfeed~* Has received immune globulin and/or blood products within 3 months prior to first dose received~* Has a history of immunosuppression resulting from disease (e.g., malignancy; human immunodeficiency virus \[HIV\] infection), or is currently taking corticosteroids or other immunosuppressive/cytotoxic therapy (cancer chemotherapy or organ transplantation)~* Has an active neoplastic disease~* Has had any infection including upper respiratory viral syndrome in the 6 weeks prior to planned collection of baseline laboratory samples~* Has received a live virus vaccine or an inactivated vaccine or is scheduled to receive a live virus vaccine or an inactivated vaccine in the period from 6 weeks prior to receipt of the first vaccine through the completion of all study visits

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Arm 1: Healthy, elderly participants (Type: None): Healthy participants 65 years old and older.
- Arm 2: Healthy, young, participants (Type: None): Healthy participants 25 to 40 years old.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Response Modifier (Arabinoxylan Rice Bran/MGN-3/Biobran) With Interferon-Alpha for HCV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with chronic HCV infection and chronic active liver diseases.~Exclusion Criteria:~* Patients diagnosed with chronic HBV , HIV infection , autoimmune disorders , any heart diseases , any kidney diseases or any blood disease , any neoplastic disorders.~* Pregnant or lactating ladies , and drug abusers will be excluded.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: ACTIVE_COMPARATOR): Patients are treated with 180µg of pegylated IFN (Pegasys-Roche) subcutaneously weekly for three months. In addition, they are given ribavirin according to their body weight (1200 mg for those over 75 kg and 1000 mg for those under 75 kg).
- Group 2 (Type: EXPERIMENTAL): Patients are treated with Biobran, at a dose of 1g per day, allocated in packets, taken orally with meals for the three months duration of the study. Biobran is a denatured hemicellulose that is obtained by reacting rice bran hemicellulose with multiple carbohydrate hydrolyzing enzymes from Shiitake mushrooms. It is a polysaccharide that contains ß-1, 3-glucans, and activated hemicellulose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Effect of ISIS GCGRRx on Hepatic Lipid and Glycogen Content in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, age 18 to 75~* BMI ≥ 25.0 kg/m2 \< 36.0 kg/m2~* HbA1c ≥ 7.5% and ≤ 10.5%~* Type 2 Diabetes Mellitus and on stable dose of Metformin. Patients must have been on a stable dose of oral metformin (at least 1000 mg/day) for a minimum of 3 months prior to screening evaluation and will be required to continue their stable dose of metformin throughout the study. Patients on a stable dose of metformin plus a sulfonylurea (SU) or metformin plus a dipeptidyl peptidase-IV (DPPIV) inhibitor for a minimum of 3 months prior to Screening evaluation may be allowed~* Agree to conduct home-based (fasted) blood glucose testing as directed~Exclusion Criteria:~* Clinically significant abnormalities in medical history or physical exam~* Show evidence of uncorrected hypothyroidism or hyperthyroidism~* History of liver transplantation or renal dialysis~* History of liver disease~* History of greater than 3 episodes of severe hypoglycemia within 6 months of screening~* Treatment with any other antidiabetic drug(s) other than metformin, SU or DPPIV within 3 months of screening~* History of diabetic ketoacidosis~* Any other significant illness or condition that may interfere with the patient participating or completing the study~* Inability or unwillingness to comply with protocol or study procedures -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ISIS-GCGRRx (Type: EXPERIMENTAL): ISIS-GCGRRx once weekly dosing for 13 weeks
- Placebo (Type: PLACEBO_COMPARATOR): once weekly dosing for 13 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BELOVA Data Collection: Safety and Efficacy of Frontline Bevacizumab Treatment in Participants With Ovarian Cancer 70 Years and Older

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Aged 70 years and older~* No treatment with any other investigational agent within 28 days or 2 half-lives (whichever is longer) prior to enrollment~Exclusion Criteria:~* Contraindications, warnings, and precautions for bevacizumab

- Gender: FEMALE
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Elderly Participants with Ovarian Cancer (Type: None): Elderly participants aged 70 years and older administered frontline treatment for International Federation for Gynecology and Obstetrics (FIGO) stage IV epithelial ovarian, fallopian tube, or primary peritoneal cancer with bevacizumab in combination with chemotherapy according to standard of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZ

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~- Healthy women between 18 and 45 requesting oral contraception. Smokers may not exceed 35 years of age.~Exclusion Criteria:~- The use of steroidal oral contraceptives, or any drug that could alter oral contraception metabolism will be prohibited during the study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Flexible (extended) regimen no. 1 of EE20/DRSP (BAY86-5300) (Type: EXPERIMENTAL): Minimum of 3 cycles of treatment, each cycle comprising 120 days (maximum) intended treatment with one tablet daily of BAY86-5300 (SH T00186D) followed by a 4-day tablet-free interval. If 3 consecutive days of bleeding and/or spotting occurred between days 25 to 120 of the treatment cycle, a 4-day tablet-free interval was advised. The minimum period between 2 tablet-free intervals was 24 days. After each 4-day tablet-free interval, a new 124-day intended treatment cycle was to be restarted, resulting in a minimum of 3 and maximum of 13 withdrawal bleeding episodes during one year of treatment
- Flexible (extended) regimen no. 2 of EE20/DRSP (BAY86-5300) (Type: EXPERIMENTAL): Minimum of 3 cycles of treatment, each cycle comprising 120 days (maximum) uninterrupted treatment with one tablet daily of BAY86-5300 (SH T00186D) and a 4-day tablet-free interval. Subjects were permitted to schedule their withdrawal bleeding (ie, 4-day tablet-free interval) at any time between days 25 to 120 of the cycle. Subjects had the option to follow the bleeding rules of the flexible (extended) regimen no. 1 of BAY86-5300. The minimum period between 2 tablet-free intervals was 24 days. After each 4-day tablet-free interval, a new 124-day intended treatment cycle was to be restarted, resulting in a minimum of 3 and maximum of 13 withdrawal bleeding episodes during one year of treatment.
- Conventional regimen of EE20/DRSP (YAZ, BAY86-5300) (Type: ACTIVE_COMPARATOR): 13 cycles of treatment, each cycle comprising an intake of one tablet daily with 24 days of active tablets of BAY86-5300 (YAZ, SH T00186D) followed by 4 days of tablets without active substance (together resulting in one cycle of 24+4 standard treatment). 13 withdrawal bleeding episodes during one year of treatment were expected.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Preventing Propofol-associated Injection Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* weight \>40kg, \<100kg~* ambulatory surgery~Exclusion criteria:~* allergy to propofol or lidocaine~* taking opioids, benzodiazepines, or nonsteroidal antiinflammatory drugs (NSAIDs)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Saline pretreatment, saline admixture
- Lidocaine pretreatment (Type: ACTIVE_COMPARATOR): Lidocaine pretreatment / saline-propofol admixture
- Lidocaine-Propofol admixture (Type: ACTIVE_COMPARATOR): saline pretreatment / Lidocaine-propofol admixture

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Singulair(R) In Asthma And Allergic Rhinitis (0476-383)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is a user of Inhaled Corticosteroid (ICS) or ICS/Long-Acting Beta 2-Agonist (ICS/LABA) at any dosage~* Peak expiratory flow is \> or = 80% of predicted value on the day of visit 1~* Uncontrolled as per Canadian asthma consensus guidelines~Exclusion Criteria:~* Unwilling to stop regular use of histamine H1 antagonists for allergic rhinitis symptoms~* Unwilling to stop use of antihistamine eye drops or cromoglycate eye drops or ophthalmic corticosteroid

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): montelukast sodium

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus according to the World Health Organization (WHO) criteria treated with basal insulin and up to 3 of the following oral antihyperglycemic medication (OAM):~  * dipeptidyl peptidase-4 (DPP-4) inhibitors~ * sodium-glucose cotransporter (SGLT-2) inhibitors~ * biguanides~ * alpha-glucosidase inhibitors~ * sulfonlyureas~* HbA1c value of 6.5% to 10%, inclusive~* Body mass index (BMI) between 20 and 45 kilograms per meter squared (kg/m2), inclusive~Exclusion Criteria:~* Type 1 diabetes mellitus or latent autoimmune diabetes~* Any episodes of severe hypoglycemia and/or hypoglycemia unawareness within the 6 months prior to screening~* Any of the following cardiovascular (CV) conditions: acute myocardial infarction, New York Heart Association Class III or IV heart failure, or cerebrovascular accident (stroke)~* Acute or chronic hepatitis, or obvious clinical signs or symptoms of any other liver disease~* Estimated glomerular filtration rate (eGFR) \<30 milliliters/minute/1.73 m2~* Active or untreated malignancy~* Chronic (\>14 days) systemic glucocorticoid therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LY3209590 Algorithm 1 (Type: EXPERIMENTAL): Participants received loading dose followed by weekly dose of LY3209590 based on the prior randomization basal insulin dose for a period of 32 weeks by subcutaneous (SC) injection. Dose titration was done to maintain fasting blood glucose of \<140 milligram per deciliter (mg/dL).
- LY3209590 Algorithm 2 (Type: EXPERIMENTAL): Participants received loading dose followed by weekly dose of LY3209590 based on the prior randomization basal insulin dose for a period of 32 weeks by subcutaneous injection. Dose titration was done to maintain fasting blood glucose of \<120 mg/dL.
- Insulin Degludec (Type: ACTIVE_COMPARATOR): Participants received same dose of Degludec as the total basal insulin dose already administered prior to randomization. Dose was titrated to maintain fasting blood glucose of ≤100 mg/dL to achieve glycemic goal of HbA1C \<7%.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Documentation of del (17p13.1)~* Must have relapsed or refractory CLL/SLL after receiving at least 1 prior line of systemic therapy.~* Measurable nodal disease by computed tomography (CT)~Key Exclusion Criteria:~* History or current evidence of Richter's transformation or prolymphocytic leukemia~* Prior hematologic stem cell transplantation \<6 months from study enrollment or any ongoing GVHD~* Prior exposure to ibrutinib

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ibrutinib (Type: EXPERIMENTAL): All subjects will receive ibrutnib 420 mg (3 x 140-mg capsules) orally once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Influence of the Implant Connection on Facial Tissues Maturation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Missing teeth~* good oral hygiene~* good systemic health~Exclusion Criteria:~* lactation~* pregnancy~* heavy smoking (more than 20 cigarettes/day)~* severe medical conditions that could affect periodontal health and peri-implant tissue response~* use of drugs correlated to periodontal hypertrophy~* bone volume that required bone augmentation procedures before implant placement as well as soft tissue graft or any kind of peri-implant tissue engineering

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: ACTIVE_COMPARATOR): Anyridge (Mega'Gen, Korea) 5° conical internal hexed connection
- Group 2 (Type: ACTIVE_COMPARATOR): Core (Bioimplant, Italy) 35° conical internal hexed connection (screw-vent style)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: NeoCart Phase 2 Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients presenting with symptomatic knee pain indicative of an articular cartilage injury and able and willing to give informed consent.~Exclusion Criteria:~* Patients with any previous surgical treatment other than debridement or microfracture of the study cartilage defect.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- NeoCart (Type: EXPERIMENTAL): None
- microfracture (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Early and Intermittent Antiretroviral Therapy in Naive HIV Infected Adults

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult confirmed HIV-1 infection~* no previous treatment with antiretroviral drugs or interleukin-2~* CD4 count ≥ 500/mm3~* no active opportunistic infection~* written informed consent~Exclusion Criteria:~* non barrier contraception in women of child bearing potential, pregnant or breastfeeding woman, pregnancy project within the next 2 years~* HIV-2 infection (with or without HIV-1), recent HIV primary infection, resistance to trial drugs at study entry, Ag HBs+, HCV requiring specific therapy~* previous history of cerebrovascular accident or coronary heart disease, splenectomy~* previous CD4 count \< 400/mm3~* CD4 percentage \< 15%~* hemoglobin \< 8 g/dl, neutrophils \< 750/mm3, platelets \< 100.000/mm3, creatinine clearance \< 50 ml/mn, AST or ALT or total bilirubin \> 3 ULN

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intermittent treatment (Type: EXPERIMENTAL): 6 months on antiretroviral treatment and 6 months off treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Caudal Epidural Injections in Treatment of Chronic Low Back and Lower Extremity Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age~* History of chronic, function-limiting low back pain of at least 6 months duration~* Able to give voluntary, written informed consent to participate,~* Able to understand the investigation, cooperate with the procedures, and willing to return for follow-up~* No recent surgical procedures within last three months~Exclusion Criteria:~* Cauda Equina symptoms and/or compressive radiculopathy~* Narcotic use of no greater than 100mg/day hydrocodone, 60mg Methadone. or 100mg morphine~* Uncontrolled major Depression or uncontrolled psychiatric disorder~* Uncontrolled or acute medical illnesses~* Chronic severe conditions that could interfere with outcome assessments~* Women who are pregnant or lactating~* Subjects who have participated in a clinical study with an investigational product within 30 days of enrollment~* Patients with multiple complaints involving concomitant hip osteoarthritis~* Inability to achieve proper positioning and inability to understand informed consent and protocol~* History of adverse reaction to local anesthetic or anti-inflammatory drugs and history of gastrointestinal bleeding or ulcers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- local anesthetic (Type: ACTIVE_COMPARATOR): Group 1. local anesthetics only
- Local anesthetic with generic Celestone (Type: ACTIVE_COMPARATOR): Group 2. local anesthetic with 6mg of non-particulate Celestone
- Local anesthetic with Celestone (Type: ACTIVE_COMPARATOR): Group 3. local anesthetic with 6 mg of brand nameCelestone
- Local anesthetic with DepoMedrol (Type: ACTIVE_COMPARATOR): Group 4. local anesthetic with 40 mg of alcohol-free DepoMedrol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete